Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00697 JCO Precision Oncology no. 7 (2023) e2200697. Published online June 1, 2023. PMID: 37262390 Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors Monica F. Chen , MD1,2xMonica F. ChenSearch for articles by this author; Soo-Ryum Yang, MD3xSoo-Ryum YangSearch for articles by this author; Jinru Shia , MD3xJinru ShiaSearch for articles by this author; Jeffrey Girshman , MD4xJeffrey GirshmanSearch for articles by this author; Sippy Punn, RN5xSippy PunnSearch for articles by this author; Clare Wilhelm , PhD1xClare WilhelmSearch for articles by this author; Mark G. Kris, MD1xMark G. KrisSearch for articles by this author; Emiliano Cocco , PhD6xEmiliano CoccoSearch for articles by this author; Alexander Drilon , MD1,2xAlexander DrilonSearch for articles by this author; and Nitya Raj , MD5xNitya RajSearch for articles by this author Show More 1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY2Early Drug Development Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY3Department of Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY4Department of Radiology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY5Gastrointestinal Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY6Department of Biochemistry and Molecular Biology/Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL*M.F.C. and S.-R.Y. contributed equally to this work as cofirst authors. A.D. and N.R. contributed equally to this work as cosenior authors. https://doi.org/10.1200/PO.22.00697 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTSupported by grants from the National Cancer Institute (R01CA226864 to E.C. and A.D; and P30CA008748 to M.F.C., S.-R.Y., J.S., J.G., M.G.K., A.D., N.R.); and Nonna’s Garden Foundation (to A.D.).AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Monica F. ChenStock and Other Ownership Interests: NordiskSoo-Ryum YangHonoraria: Prime EducationConsulting or Advisory Role: InVitaeJinru ShiaConsulting or Advisory Role: PAIGE.AIMark G. KrisConsulting or Advisory Role: AstraZeneca, Pfizer, Janssen, Merus, BerGenBioTravel, Accommodations, Expenses: Genentech, AstraZenecaOpen Payments Link: https://openpaymentsdata.cms.gov/physician/markgkris/summaryEmiliano CoccoEmployment: AstraZenecaConsulting or Advisory Role: Entos Pharmaceuticals, Institutional Biosafety CommitteeResearch Funding: Innocare, Erasca IncAlexander DrilonStock and Other Ownership Interests: Treeline BiosciencesHonoraria: Pfizer, Loxo/Bayer/Lilly, IASLC, Helsinn Therapeutics, BeiGene, Remedica, TP Therapeutics, Verastem, Ignyta/Genentech/Roche, AstraZeneca, Liberum, Lungevity, NIH, PER, OncLive/MJH Life Sciences, Clinical Care Options/NCCN, Lung Cancer Research Foundation, Associazione Italiana Oncologia Toracica (AIOT), Chugai Pharma, Sirio Libanes Hospital, Answers in CME, Research to Practice, i3 Health, RV MaisConsulting or Advisory Role: Ignyta, Loxo, AstraZeneca, Pfizer, Blueprint Medicines, Genentech/Roche, BeiGene, Hengrui Therapeutics, Exelixis, Bayer, Tyra Biosciences, Takeda/Millennium, BerGenBio, MORE Health, Lilly, AbbVie, 14ner Oncology/Elevation Oncology, Monopteros Therapeutics, Novartis, EMD Serono/Merck, Repare Therapeutics, Melendi, Archer, Nuvalent, Inc, Janssen, Amgen, Merus, Axis Pharma, Medscape, Liberum, Med Learning, PeerView, EPG Health, Journal of the National Comprehensive Cancer Network, Ology Medical Education, Ology Medical Education, Clinical Care Options, touchIME, Entos, Prelude Therapeutics, Applied Pharmaceutical Science, Treeline Biosciences, Monte Rosa TherapeuticsResearch Funding: Foundation MedicinePatents, Royalties, Other Intellectual Property: Wolters Kluwer (Royalties for Pocket Oncology)Other Relationship: Merck, GlaxoSmithKline, Teva, Taiho Pharmaceutical, Pfizer, PharmaMar, Puma Biotechnology, Pfizer, Merus, Boehringer IngelheimNitya RajConsulting or Advisory Role: Ipsen, HRA Pharma, Advanced Accelerator Applications/Novartis, ProgenicsResearch Funding: Novartis (Inst), Xencor (Inst), Corcept Therapeutics (Inst), ITM Isotope Technologies Munich (Inst), Camarus AB (Inst)No other potential conflicts of interest were reported.